Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
How Do Younger People Fare With Stool Tests for CRC Screening?
2.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
3.
How breast tissue density affects your risk of breast cancer
4.
A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.
5.
SBRT May Beat Brachytherapy in Prostate Cancer
1.
Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy
2.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
3.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
4.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
5.
What You Need To Know About Trametinib: A Miracle Cancer Treatment?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation